Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. - Wikidata - awgldk - TriplyDB

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

http://www.wikidata.org/entity/Q42547184

about

Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure Drug therapy for heart failure in older patients-what do they want?Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis Major beta blocker mortality trials in chronic heart failure: a critical review.Clinical Pharmacology of Carvedilol.The effect of beta-blockers on health-related quality of life in patients with heart failure.beta-blockers in heart failure: recently completed and ongoing clinical trials.beta-Blockers in congestive heart failure.Beta blockers for CHF. Adrenergic blockade dramatically reduces morbidity and mortality.Carvedilol in the treatment of chronic heart failure.Economics of chronic heart failure.Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.Role of race in the pharmacotherapy of heart failure.Are all beta blockers the same for heart failure?Is heart failure in African Americans a distinct entity?Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization.Valsartan in chronic heart failure.Effect of beta-blocker therapy on functional status in patients with heart failure--a meta-analysis.Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol.Carvedilol: use in chronic heart failure.Quality of life assessment in heart failure interventions: a 10-year (1996-2005) review.Role of carvedilol controlled-release in cardiovascular disease.Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.Assessing quality-of-life outcomes in cardiovascular clinical research.Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope.Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy.Beta blockers in heart failure haemodynamics, clinical effects and modes of action The effects of alpha and beta blockade on ventilatory responses to exercise in chronic heart failure.Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.Exercise capacity and ventilatory response during exercise in COPD patients with and without β blockade.Effect of vasodilatory beta-adrenoceptor blockers on cardiovascular haemodynamics in anaesthetized rats.Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure.Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.The effect of physical training in chronic heart failure.

P2860

Q22306530-FD418F52-9EC6-4B93-BD42-128F14D5F62C Q26741100-6EE2F860-D945-4946-9085-7430E19DF18B Q28068618-C66A99A3-5CED-475B-905F-F6BEFD5A0A16 Q28083086-E7402FE6-222C-47AD-8D48-6EC5BA6066F6 Q30239022-40B4B7B0-22F6-43B7-B665-C4BE79F48B04 Q33780871-03003FEF-1CDC-4FAE-B4EC-6FBAE22A236A Q33843419-5162CAC6-3EC0-4674-B407-33B14FA14B8E Q33942862-26D26604-6CF0-41FD-AB52-177CB86EF2FE Q34074729-AE61D8A8-CD8F-40F2-B10C-F3E8AB3B73AE Q34119535-0DF88828-5801-43CC-98EE-0E8B218D884E Q34193584-B10E2180-0BEB-4686-9EFB-52C4C9DB3B39 Q34241046-C154175C-6276-403A-99FF-2F8F7E24D60D Q34264676-9E347503-0608-449F-B7F1-8EBF471A4FB9 Q34495751-529A28E1-E982-4D5B-9702-7FCD8195A0BD Q34564305-555B9CF3-CB5E-4BE2-801E-5E2A689248FF Q34656022-FBB13E54-71E6-4F86-B330-D2826CFB236C Q35205765-8FEB5CD9-A4AE-4ADB-BB52-848F9F1D2B42 Q35582518-DA176AFF-CABA-4008-BBBF-186A4EB498D5 Q35709754-24953073-23B2-46CE-A4A4-78DECFDF8525 Q36027661-C47EC9B8-5AA4-457C-AB7A-9E3340E04446 Q36352751-A2F08960-90C3-4E3C-B45D-F84ED71080BE Q36675404-A17B928A-BD41-4C19-90B8-55F41D50919E Q36691623-080D1F26-2780-49E1-94D5-95F6C20C02EF Q36966553-8F713908-586F-4F10-B664-10E37E504C72 Q37472042-EAA9BE6F-F6F7-4726-B02D-1992D37D544B Q38074639-182461D0-0875-447B-B5B8-52421C080C6A Q38737960-C99E0553-32F5-45A1-94E9-77BC56D5FD49 Q41845098-404099EA-68F7-4635-81FF-F13F5A88BED8 Q42111594-56A63BCC-91DE-442E-BE8D-B02A26844B02 Q42174779-7ABF9923-0091-4C8E-AC19-955C01C78020 Q42332443-882D6F01-FDB4-4B89-92A6-01F3BF1EAF05 Q43014317-2F867024-69FD-494B-BB44-C1BD8A2B04D9 Q43711820-0D80B944-99A9-4B44-B3F7-E5BC43A43FB4 Q43747633-130A56C3-CC00-4F26-A6AF-8E9E9AACDF0D Q43925199-7FA2DA72-3CF4-41A2-9786-FD4595DDB8F2 Q44230621-006833AB-1295-41A6-97E7-ED12497DB967 Q46514958-CFF463BF-89E0-4F53-8F8B-F0DEDEADD621 Q46514972-6A718786-3FC5-438C-8785-D16252653E97 Q46616130-67846219-7873-491B-8F7F-0BDCB7833340 Q48759570-AD8082ED-DB3F-492A-B00B-910244811568

P2860

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

http://www.wikidata.org/entity/Q42547184

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@en

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@nl

type

label

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@en

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@nl

prefLabel

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@en

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@nl

P1433

Q42547184-E01DC70F-E03D-41CF-BE9B-E22B5F6261D3

P1476

Q42547184-E7E01411-B96A-431C-A4AA-0A31FDC28B42

P2093

Q42547184-0F1EA405-2DB6-4606-B409-CA47C8FFEF47

Q42547184-21E53CA0-43F0-4DD4-9B4B-A154CF58113E

Q42547184-2C32E556-7550-462C-9E07-30A499F19542

Q42547184-6F3C6A26-629C-46E7-8C77-6BB849079D39

Q42547184-7D559AD1-1EC3-4D33-A175-5F42467E67FF

Q42547184-824B23BD-BC5E-466E-BB64-38E813EDEB2E

Q42547184-8C83F1B0-D9B4-40BF-BA5D-2D8539D70FA3

Q42547184-A8F1800B-92F3-44AC-BD9E-D5F0870D914A

Q42547184-A9447452-DFC4-4E8D-8CB6-EF2DB2FC8ED2

Q42547184-CF89C0F4-C32E-4D86-8330-8EC6854126CF

P304

Q42547184-1F228296-6E1A-4226-BB28-30398AF0B046

P31

Q42547184-CB6474E6-74B0-420C-BE62-7F7A943E912D

P356

Q42547184-506D9824-6CC8-4AC3-BE97-203C6B057371

P433

Q42547184-8BC655D2-E843-41FD-B72A-AC4D96E7ABF3

P478

Q42547184-3E683AF8-D8B6-4A46-A4A1-802151892F28

P577

Q42547184-9D3B36C3-2B2A-4E95-A6C8-5E13DF05FB0D

P698

Q42547184-0C0AD0FE-3449-4123-989A-5409EB817196

P921

Q42547184-D11890D2-D813-4C37-87D5-B30CE19A006A

P356

S1071-9164(97)90013-0

P1433

Journal of Cardiac Failure

P1476

Safety and efficacy of carvedi ...... lol Heart Failure Study Group.

@en

P2093

E M Gilbert

http://www.w3.org/2001/XMLSchema#string

J N Cohn

http://www.w3.org/2001/XMLSchema#string

K A Narahara

http://www.w3.org/2001/XMLSchema#string

M A Lukas

http://www.w3.org/2001/XMLSchema#string

M B Fowler

http://www.w3.org/2001/XMLSchema#string

M Packer

http://www.w3.org/2001/XMLSchema#string

M R Bristow

http://www.w3.org/2001/XMLSchema#string

S K Krueger

http://www.w3.org/2001/XMLSchema#string

S T Young

http://www.w3.org/2001/XMLSchema#string

T L Holcslaw

http://www.w3.org/2001/XMLSchema#string

P304

173-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1071-9164(97)90013-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

1997-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9330125

http://www.w3.org/2001/XMLSchema#string

P921